Original language | English |
---|---|
Pages (from-to) | 1287-1289 |
Number of pages | 3 |
Journal | Movement Disorders |
Volume | 36 |
Issue number | 6 |
Early online date | 28 Apr 2021 |
DOIs |
|
Publication status | Published - Jun 2021 |
Keywords
- COVID-19
- Long COVID
- Parkinson's disease
- Post–COVID-19 syndrome
- SARS-CoV-2
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Movement Disorders, Vol. 36, No. 6, 06.2021, p. 1287-1289.
Research output: Contribution to journal › Comment/debate › peer-review
TY - JOUR
T1 - Parkinson's Disease and Post–COVID-19 Syndrome
T2 - The Parkinson's Long-COVID Spectrum
AU - Leta, Valentina
AU - Rodriguez-Violante, Mayela
AU - Abundes, Arturo
AU - Rukavina, Katarina
AU - Teo, James T.
AU - Falup-Pecurariu, Cristian
AU - Irincu, Laura
AU - Rota, Silvia
AU - Bhidayasiri, Roongroj
AU - Storch, Alexander
AU - Odin, Per
AU - Antonini, Angelo
AU - Ray Chaudhuri, Kallol
N1 - Funding Information: V.L. received honoraria for speaker‐related activities from Bial, Profile, and Britannia Pharmaceuticals. J.T.T. received research support and funding from Office of Life Sciences, InnovateUK, Bristol‐Myers‐Squibb, iRhythm Technologies, and received speaker honorarium from Bristol‐Meyers‐Squibb and Goldman Sachs. P.O. received compensation for lectures and advice from AbbVie, Bial, Britannia, Ever Pharma, Global Kinetics (GKC), Lobsor, Nordic Infucare, and Zambon. R.B. receives salary from Chulalongkorn University and stipend from the Royal Society of Thailand; has received consultancy and/or honoraria/lecture fees from Abbott, Boehringer‐Ingelheim, Britannia, Ipsen, Novartis, Teva‐Lundbeck, Takeda, and Otsuka pharmaceuticals; has received research funding from the Newton Fund, the UK government, Thailand Science, and Research Innovation Bureau, Thailand Research Fund, Crown Property Bureau, Chulalongkorn University, and the National Science and Technology Development Agency; and holds patents for a laser‐guided walking stick, portable tremor device, nocturnal monitoring, and electronic Parkinson's disease symptom diary as well as copyright on Parkinson's mascot, dopamine lyrics and teaching video clips for common nocturnal and gastrointestinal symptoms for Parkinson's disease. A. Antonini has received compensation for consultancy and speaker related activities from Union Chimique Belge (UCB), Boehringer Ingelheim, Britannia, AbbVie, Kyowa Kirin, Zambon, Bial, Neuroderm, Theravance Biopharma, Roche and receives research support from Chiesi Pharmaceuticals, Bial, Lundbeck, Horizon 2020 (Grant 825,785), Horizon2020 (Grant 101,016,902), Ministry of Education University and Research (Grant ARS01_01081), and the Cariparo Foundation. He serves as consultant for Boehringer–Ingelheim for legal cases on pathological gambling. K.R.C. has received honoraria for advisory boards from AbbVie, UCB, Pfizer, Jazz Pharma, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, and Scion; honoraria for lectures from AbbVie, Britannia Pharmaceuticals, UCB, Mundipharma, Zambon, Novartis, Boehringer Ingelheim, Neuroderm, and Sunovion; grants (investigator initiated) from Britannia Pharmaceuticals, AbbVie, UCB, GKC, and Bial; and academic grants from Innovative Medicines Initiative European Union (IMI EU), Parkinson's UK, National Institute for Health Research, Parkinson's disease non‐motor study group (PDNMSG), European Union (EU) (Horizon 2020), Kirby Laing Foundation, Parkinson's Foundation (PF) (USA), and Medical Research Council (MRC). Funding Information: The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), National Institute for Health Research (NIHR) or Department of Health. The authors acknowledge the support of the International Parkinson and Movement Disorder Society Non-Motor PD Study Group, the NIHR London South Clinical Research Network, and the NIHR Biomedical Research Centre. This article represents independent collaborative research part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The authors would also like to thank the patients of the King's Electronic Records Research Committee, UK; all clinicians and frontline staff engaged in the care of patients with COVID-19 and research activity at King's College and Princess Royal Hospitals, London, in particular Daniel van Wamelen, Lucia Batzu, Miriam Parry, Jenny Natividad, Olabisi Awogbemila, Aleksandra Podlewska, Dhaval Trivedi, Jonathon Samuel, Pavlos Zinzalias, Juliet Staunton, and Alexandra Rizos; as well as clinicians and frontline staff at the Instituto Nacional de Neurolog?a y Neurocirug?a Manuel Velasco Su?rez, Mexico City, Mexico; at the Parkinson and Movement Disorders Unit in Padua, Italy; and at the Department of Neurology, Transilvania University of Bra?ov, Bra?ov, Romania. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6
Y1 - 2021/6
KW - COVID-19
KW - Long COVID
KW - Parkinson's disease
KW - Post–COVID-19 syndrome
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85105419625&partnerID=8YFLogxK
U2 - 10.1002/mds.28622
DO - 10.1002/mds.28622
M3 - Comment/debate
C2 - 33890344
AN - SCOPUS:85105419625
SN - 0885-3185
VL - 36
SP - 1287
EP - 1289
JO - Movement Disorders
JF - Movement Disorders
IS - 6
ER -